C lostridium difficile infection (CDI) is the leading cause of nosocomial infectious diarrhea in developed countries. 1 The composition of human gut microbiome is associated with the development of CDI. This theory is bolstered by the increase in CDI risk after antibiotic exposure and the success of fecal microbiota transplant in treating refractory CDI.
C lostridium difficile infection (CDI) is the leading cause of nosocomial infectious diarrhea in developed countries. 1 The composition of human gut microbiome is associated with the development of CDI. This theory is bolstered by the increase in CDI risk after antibiotic exposure and the success of fecal microbiota transplant in treating refractory CDI. 2 Use of non-digestible oligosaccharides (eg, lactulose, oligofructose) as prebiotics may be a safe and effective approach to restoring or strengthening colonization resistance against CDI by selectively promoting the growth of a host's indigenous microbiota. 3, 4 Lactulose has been shown to alter the colonic microenvironment in ways that inhibit C difficile growth. 3 We sought to determine whether lactulose use was associated with a decreased risk of CDI.
Methods
We conducted a matched nested case-control study among end-stage liver disease (ESLD) patients admitted to an academic health system between 2005 and 2013. Patients were identified by the presence of ESLD on discharge diagnosis codes. 5 Admissions were excluded if the patient was hospitalized for less than 24 hours, had incomplete medical records, had undergone prior liver transplantation, or had a history of CDI.
Cases were identified by incident diagnosis of CDI during admission on the basis of stool toxin or polymerase chain reaction testing for toxigenic genes. For each case, controls were selected by using incidence density sampling matching on age, sex, admission date, and duration of hospital stay. The exposure of interest was at least 10 g/day of lactulose for more than 48 hours.
Conditional logistic regression was used to calculate the odds ratio (OR) for CDI risk associated with lactulose use. We examined the following potential confounders: Model for End Stage Liver Disease score, intensive care unit stay, race, type of hepatic decompensation, use of rifaximin, metronidazole, or other antibiotics grouped by class. Variables were included in the multivariate model if their inclusion changed the crude OR for CDI risk by more than 5%.
Results
The study included 112 eligible cases matched with 928 controls. The 2 groups differed in history of hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), and use of rifaximin, metronidazole, and cephalosporins ( Table 1) .
The prevalence of lactulose use was significantly lower among cases than controls (crude OR, 0.48; 95% confidence interval [CI], 0.31-0.74; P < .001). A diagnosis of HE as well as exposure to rifaximin, metronidazole, and cephalosporins significantly changed the crude OR by >5%. HE was automatically excluded from the regression model because it was highly correlated with rifaximin use. The adjusted OR accounting for these variables was 0.60 (95% CI, 0.37-0.97; P ¼ .04).
In secondary analyses, the effect estimates were unchanged when excluding patients who received rifaximin (adjusted OR, 0.52; 95% CI, 0.31-0.89; P ¼ .02) or had SBP (OR, 0.60; 95% CI, 0.36-1.01; P ¼ .053). There was no difference in the frequency of CDI testing between the lactulose users (23%) vs non-users (19%), P ¼ .3.
antibiotics. This is consistent with a prior report that oligofructose reduces the risk of relapsing CDI. 6 There are several important limitations to this study. Several strategies were used to minimize confounding. The cases and controls were matched on key characteristics. The primary association remained significant even after accounting for measured confounders in a multivariable model. Secondary analyses, restricted among those without SBP or rifaximin, also yielded similar results to our primary analysis. Nevertheless, we cannot completely exclude residual confounding.
We found that lactulose users were actually tested more frequently for CDI, making differential testing an unlikely explanation for our results. Finally, although prior studies have demonstrated a similar effect of lactulose on geriatric inpatients, 7 the generalizability of our finding in non-cirrhotic patients is unclear.
In conclusion, lactulose use among hospitalized ESLD patients was associated with a significantly lower risk of CDI. These results will need confirmation in other patient populations and in a prospective setting, but they lend further support to the importance of the gut microbiome in CDI pathogenesis and the role of prebiotics such as lactulose in CDI prevention. 
